[HTML][HTML] The Capio Prostate Cancer Center Model for Prostate Cancer Diagnostics—Real-world Evidence from 2018 to 2022
T Palsdottir, H Söderbäck, F Jäderling… - European Urology Open …, 2024 - Elsevier
Abstract Background The Capio Prostate Cancer Center (Capio PCC) in Stockholm,
Sweden, adopts a comprehensive diagnostic approach, utilizing prostate-specific antigen …
Sweden, adopts a comprehensive diagnostic approach, utilizing prostate-specific antigen …
265P The Capio Prostate Cancer Center model for prostate cancer diagnostics using Stockholm3, MRI and targeted biopsies: Real-world evidence from 2018 to 2022
H Vigneswaran, H Söderbäck, F Jäderling… - Annals of …, 2023 - annalsofoncology.org
Background The Capio Prostate Cancer Center (Capio PCC) handles aproximately 25% of
prostate cancer (PC) care in Stockholm, Sweden. The Capio PCC Model utilizes Stockholm3 …
prostate cancer (PC) care in Stockholm, Sweden. The Capio PCC Model utilizes Stockholm3 …
Improved prostate cancer diagnostics with a struc-tured pathway including the Stockholm3 test and MRI--targeted biopsies-experiences from Capio S: t Göran Prostate …
M Bergman, F Jäderling, E Meurling… - …, 2018 - europepmc.org
Capio S: t Göran Prostate Cancer Center is located in Stockholm and offers testing for
prostate cancer using a structured pathway including the blood-test Stockholm3 and MRI …
prostate cancer using a structured pathway including the blood-test Stockholm3 and MRI …
[HTML][HTML] Improving the early detection of clinically significant prostate cancer in men in the challenging prostate imaging-reporting and data system 3 category
J Morote, M Campistol, M Triquell, A Celma… - European Urology Open …, 2022 - Elsevier
Abstract Background Prostate Imaging-Reporting and Data System (PI-RADS) category 3 is
a challenging scenario for detection of clinically significant prostate cancer (csPCa) and …
a challenging scenario for detection of clinically significant prostate cancer (csPCa) and …
[HTML][HTML] Evaluation of the changing landscape of prostate cancer diagnosis and management from 2005 to 2016
KR Carlaw, HH Woo - Prostate International, 2017 - Elsevier
Background Approaches to prostate cancer (PCa) diagnosis and treatment have evolved
significantly over past decades. There has been an increasing focus on minimizing …
significantly over past decades. There has been an increasing focus on minimizing …
PD39-02 THE CAPIO S: T GORAN MODEL FOR PROSTATE CANCER DIAGNOSIS USING STOCKHOLM3, MAGNETIC RESONANCE IMAGING AND TARGETED …
T Palsdottir, H Grönberg, H Vigneswaran… - Journal of …, 2023 - journals.lww.com
METHODS: In 2017, the PC center incorporated the use of Stockholm3 as a reflex test for
men with PSA levels> 1.5 ng/mL between 45-75 years without a previous diagnosis of PC …
men with PSA levels> 1.5 ng/mL between 45-75 years without a previous diagnosis of PC …
Structured population-based prostate-specific antigen screening for prostate cancer: the European Association of Urology position in 2019
G Gandaglia, P Albers, PA Abrahamsson, A Briganti… - European urology, 2019 - Elsevier
Prostate cancer (PCa) is one of the first three causes of cancer mortality in Europe.
Screening in asymptomatic men (aged 55–69 yr) using prostate-specific antigen (PSA) is …
Screening in asymptomatic men (aged 55–69 yr) using prostate-specific antigen (PSA) is …
External validation of the Rotterdam prostate cancer risk calculator within a high-risk Dutch clinical cohort
MJ Hagens, PJ Stelwagen, H Veerman, SP Rynja… - World Journal of …, 2023 - Springer
Purpose This study aims to externally validate the Rotterdam Prostate Cancer Risk
Calculator (RPCRC)-3/4 and RPCRC-MRI within a Dutch clinical cohort. Methods Men …
Calculator (RPCRC)-3/4 and RPCRC-MRI within a Dutch clinical cohort. Methods Men …
[HTML][HTML] A Head-to-head Comparison of Prostate Cancer Diagnostic Strategies Using the Stockholm3 Test, Magnetic Resonance Imaging, and Swedish National …
M Waldén, M Aldrimer, JH Lagerlöf, M Eklund… - European Urology Open …, 2022 - Elsevier
Background Strategies for early detection of prostate cancer aim to detect clinically
significant prostate cancer (csPCa) and avoid detection of insignificant cancers and …
significant prostate cancer (csPCa) and avoid detection of insignificant cancers and …
Reducing the demand for magnetic resonance imaging scans and prostate biopsies during the early detection of clinically significant prostate cancer: Applying the …
J Morote, Á Borque-Fernando, LE Esteban… - … Oncology: Seminars and …, 2024 - Elsevier
Purpose To analyze the reduction in multiparametric magnetic resonance imaging (mpMRI)
demand and prostate biopsies after the hypothetical implementation of the Barcelona risk …
demand and prostate biopsies after the hypothetical implementation of the Barcelona risk …